Boston Scientific
(NYSE: BSX)
announced today that the FDA approved its Vercise Neural Navigator 5 software.
When used as part of the Vercise Genus deep brain stimulation (DBS) systems, the software offers clinicians simple, actionable data. It enables efficient programming in the treatment of people with Parkinson’s disease or essential tremor.
Vercise Genus delivers targeted electrical stimulation through surgically implanted leads in the brain connected to implantable pulse generators (IPGs). The portfolio received approval for conditional use in a magnetic resonance imaging (MRI) environment in 2021. It consists of Bluetooth-enabled, rechargeable and non-rechargeable, IPGs that power the Vercise Cartesia directional leads.
Boston Scientific’s newly approved software offers the latest addition to the fully integrated image-guided portfolio of DBS systems. Marlborough, Massachusetts-based Boston Scientific developed the Vercise Neural Navigator 5 software with StimView XT technology in collaboration with Brainlab AG.
The company said the tools demonstrate a reduction in programming time by 56%. They also provide real-time visualization and stimulation of each person’s unique brain anatomy.
How the Boston Scientific software benefits clinicians
Boston Scientific’s Vercise software includes an enhanced user interface that displays patient data in a simplified format. It gives clinicians access to advanced settings for increased therapy delivery, too. The company said it designed the software to enable more flexibility to better manage individual patients at different stages.
Dr. Mustafa Saad Siddiqui said in a news release that the software enables the optimization of treatment benefits for each patient. Siddiqui serves as professor of neurology and neurosurgery at Wake Forest School of Medicine and medical director of the DBS program at Atrium Health Wake Forest Baptist.
“Developing meaningful tools to help physicians provide personalized treatments for their patients delivers on our promise to advance our technologies for people living with neurological conditions,” said Jim Cassidy, president, Neuromodulation, Boston Scientific. “Providing effective DBS therapy is complex and can be time-consuming. This software will help streamline the process and allow for more doctor-patient interaction time.”